

IN THE CLAIMS

Please cancel claims 3 and 6-12 without prejudice.

Please amend the following claims which are pending in the present application:

1. (Currently amended) A method of preparing a pharmaceutical composition comprising processed ginseng extract ~~obtained by the steps essentially comprising acid treating of ginseng extract and subsequent fermentation treating with lactic acid bacteria or intestinal bacteria~~, as an active ingredient in an effective amount, ~~effective to treat or prevent together with a pharmaceutically acceptable carrier, for the treating or preventing human or mammal suffering from brain strokes and brain diseases~~, wherein the method comprises the steps of treating ginseng with acid solution and subsequent fermentation with lactic acid bacteria ~~together with a pharmaceutically acceptable carrier~~.

2. (Currently amended) The method ~~pharmaceutical composition effective for treating or preventing human or mammal suffering from brain strokes and brain diseases~~ according to claim 1, wherein said ginseng comprises the root, stem, petal, leaf, fruit and tissue cultivates thereof.

3. (Cancelled)

4. (Currently amended) The method ~~pharmaceutical composition effective for treating or preventing human or mammal suffering from brain strokes and brain diseases~~ according to claim 1, wherein said lactic acid bacteria belongs to Bifidobacterium genus or Lactobacillus genus bacteria.

5. (Currently amended) The method ~~pharmaceutical composition effective for treating or preventing human or mammal suffering from brain strokes and brain diseases~~ according to claim 4, wherein said lactic acid bacteria comprises at least one or the mixture thereof selected from the group consisting of *Bifidobacterium infantis*, *Bifidobacterium bifidum*, *Lactobacillus lactis*, *Clostridium butyricum*, *Bifidobacterium* K-103, *Bifidobacterium* K-506, *Bifidobacterium* K-513, *Bifidobacterium* K-525, *Bifidobacterium* KK-1 and *Bifidobacterium* KK-2.

6-12. (Cancelled)

SUMMARY

Applicant believes that the above remarks are fully responsive to the Office Action dated July 13, 2006. If the Examiner has any questions, Applicant respectfully requests that the Examiner contact the undersigned by telephone at (408) 720-8300.


DEPOSIT ACCOUNT AUTHORIZATION

Please charge any shortages and credit any overages to Deposit Account No. 02-2666.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP

Date: August 10, 2006



Stephen M. De Klerk
Reg. No. 46,503

12400 Wilshire Boulevard
Seventh Floor
Los Angeles, California 90025-1026
(408) 720-8300